Monopar Therapeutics (MNPR) Long-Term Investments (2022 - 2025)

Monopar Therapeutics has disclosed Long-Term Investments across 4 years of filings, most recently posting $78.6 million for Q4 2025.

• Long-Term Investments for Q4 2025 came in at $78.6 million, up 445.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $78.6 million (up 445.75% YoY), and the FY2025 annual result was $78.6 million, up 445.75% from the prior year.
• Long-Term Investments came in at $78.6 million for Q4 2025 at Monopar Therapeutics, up from $16.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $78.6 million in Q4 2025 to a low of $985730.0 in Q1 2024.
• The 4-year median for Long-Term Investments is $6.0 million (2023), against an average of $14.2 million.
• Across the five-year window, Long-Term Investments plunged 83.43% in 2024 and soared 1405.61% in 2025, its largest moves.
• Monopar Therapeutics' Long-Term Investments stood at $4.9 million in 2022, then slumped by 39.61% to $3.0 million in 2023, then soared by 383.17% to $14.4 million in 2024, then surged by 445.75% to $78.6 million in 2025.
• The last three Long-Term Investments figures came in at $78.6 million (Q4 2025), $16.0 million (Q3 2025), and $13.7 million (Q2 2025), per Business Quant data.